Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?

Atrium Therapeutics (RNA) reported Q2 2026 results, highlighting FDA clearance for ATR 1072 and a $15M milestone payment from Bristol Myers Squibb. The company has $263.9M in cash, enough to fund operations through mid-2028. However, expenses outpaced revenue, with $25.6M in costs against $3M in collaboration revenue. Clinical trials are in early stages, with data expected in H2 2027.

Bristol Myers Squibb and Novartis halted clinical trials for CAR-T therapies targeting autoimmune diseases due to safety concerns. Bristol Myers paused a zola-cel study after detecting ICANS cases, while Novartis suspended rap-cel trials following three patient deaths. Both companies are investigating the issues, with Bristol Myers reporting non-fatal effects and Novartis analyzing data. The trials aimed to treat diseases like lupus and rheumatoid arthritis, with initial results showing promise.

Bristol Myers Squibb (BMY) reported five-year data for Camzyos, showing sustained efficacy and safety in treating obstructive hypertrophic cardiomyopathy, supported by real-world studies. The data strengthens Camzyos' market position and may influence clinical management. The company projects $40B revenue and $8.3B earnings by 2029, with analysts' estimates varying. The pause in zola cel trials highlights risks in BMS's pipeline.

Bristol Myers Squibb (BMY) presented positive five-year data for Camzyos at ESC 2026, showing sustained efficacy and safety in treating oHCM. Sales surged 74% YoY to $729M in H1 2026. The FDA accepted a sNDA for adolescent use, with a decision expected by Sept. 30, 2026. Competitors include Cytokinetics (CYTK) with Myqorzo and Edgewise Therapeutics (EWTX) with EDG-7500. BMY shares gained 20.3% YTD, trading at 10.35X forward earnings.

Novartis halted clinical trials for its CAR T therapy rapcabtagene autoleucel after three patient deaths due to severe immune reactions. Bristol Myers Squibb also paused trials for its competitor product zola-cel, citing reversible inflammatory events. Both therapies target CD19, a protein linked to immune responses, but can cause severe immune reactions. Neither company has identified a cause.

Novartis halted eight clinical trials of its experimental cell therapy rap-cel after three patients died from severe immune reactions. The pause affects trials for autoimmune and neurological disorders. Novartis is reviewing the deaths and sharing information with health authorities. Bristol Myers also paused studies of its rival CAR T-cell treatment zola-cel. Novartis shares rose 4% on Tuesday.